BOURLA ALBERT 4

What Happened
Albert Bourla, Pfizer’s Chairman & CEO and a director, was granted 1,630 derivative units (phantom shares) on March 13, 2026. The units are recorded at $26.58 each, for a total grant value of $43,325 (reported as a derivative award, transaction code A). This is an award/grant rather than an open-market purchase or sale.

Key Details

• Transaction date: 2026-03-13; Form 4 filed: 2026-03-16. No late-filing indication in the filing.
• Units granted: 1,630 units at $26.58 per unit; total reported value $43,325.
• Nature of instrument: Derivative units that represent phantom shares (Footnote F1).
• Settlement and transferability: Units were granted under the Pfizer Nonfunded Deferred Compensation and Supplemental Savings Plan and are settled in cash after the reporting person’s separation from service; they may be transferred into an alternative investment account at any time (Footnote F2).
• Shares owned after transaction: Not specified in the reported Form 4.

Context
This grant is a deferred-compensation award (phantom share units) rather than actual common stock. Phantom units typically track equity value for compensation purposes but are settled in cash upon separation, so they do not immediately change share ownership or voting rights. Such awards are routine executive compensation actions and do not, by themselves, indicate a buy/sell signal for company stock.